Publikationen, an denen er mitarbeitet Jesús María Hernández Rivas (26)

2024

  1. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

2023

  1. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  2. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

2022

  1. Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia

    Molecular Oncology, Vol. 16, Núm. 16, pp. 2899-2919

2020

  1. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia

    British Journal of Haematology

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2017

  1. Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes

    Cancer Letters, Vol. 409, pp. 42-48

2016

  1. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

    Nature Communications, Vol. 7

  2. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations

    Oncotarget, Vol. 7, Núm. 49, pp. 80916-80924

  3. Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes

    Genes Chromosomes and Cancer, Vol. 55, Núm. 4, pp. 322-327

2015

  1. Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations

    British Journal of Haematology

  2. Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia

    Leukemia and Lymphoma

2014

  1. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm

    Leukemia, Vol. 28, Núm. 4, pp. 823-829

  2. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: Different genetic mechanisms but equivalent poorer clinical outcome

    Genes Chromosomes and Cancer, Vol. 53, Núm. 9, pp. 788-797

2013

  1. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, Núm. 45, pp. 18250-18255

2012

  1. Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, Núm. 26, pp. 10534-10539

  2. High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma

    British Journal of Haematology, Vol. 158, Núm. 6, pp. 712-726

2011

  1. Cytogenetic risk stratification in chronic myelomonocytic leukemia

    Haematologica, Vol. 96, Núm. 3, pp. 375-383

  2. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia

    Haematologica, Vol. 96, Núm. 10, pp. 1448-1456

  3. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

    Leukemia, Vol. 25, Núm. 1, pp. 110-120